DK2707505T3 - Spektral billeddannelse til måling af nukleære patologiske træk i cancerceller fremstillet til in situ analyse - Google Patents

Spektral billeddannelse til måling af nukleære patologiske træk i cancerceller fremstillet til in situ analyse Download PDF

Info

Publication number
DK2707505T3
DK2707505T3 DK12725639.4T DK12725639T DK2707505T3 DK 2707505 T3 DK2707505 T3 DK 2707505T3 DK 12725639 T DK12725639 T DK 12725639T DK 2707505 T3 DK2707505 T3 DK 2707505T3
Authority
DK
Denmark
Prior art keywords
cancer
nuclear
data
rearrangement
cell
Prior art date
Application number
DK12725639.4T
Other languages
English (en)
Inventor
Francesca Demichelis
Karl Garsha
Phillip C Miller
Ray B Nagle
Michael Otter
Mark A Rubin
Gary Anthony Pestano
Original Assignee
Ventana Med Syst Inc
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc, Univ Cornell filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of DK2707505T3 publication Critical patent/DK2707505T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01H—ELECTRIC SWITCHES; RELAYS; SELECTORS; EMERGENCY PROTECTIVE DEVICES
    • H01H35/00—Switches operated by change of a physical condition
    • H01H35/14—Switches operated by change of acceleration, e.g. by shock or vibration, inertia switch
    • H01H35/146—Switches operated by change of acceleration, e.g. by shock or vibration, inertia switch operated by plastic deformation or rupture of structurally associated elements
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
    • H01M50/00—Constructional details or processes of manufacture of the non-active parts of electrochemical cells other than fuel cells, e.g. hybrid cells
    • H01M50/50—Current conducting connections for cells or batteries
    • H01M50/572—Means for preventing undesired use or discharge
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
    • H01M50/00—Constructional details or processes of manufacture of the non-active parts of electrochemical cells other than fuel cells, e.g. hybrid cells
    • H01M50/50—Current conducting connections for cells or batteries
    • H01M50/572—Means for preventing undesired use or discharge
    • H01M50/574—Devices or arrangements for the interruption of current
    • H01M50/578—Devices or arrangements for the interruption of current in response to pressure
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
    • H01M50/00—Constructional details or processes of manufacture of the non-active parts of electrochemical cells other than fuel cells, e.g. hybrid cells
    • H01M50/50—Current conducting connections for cells or batteries
    • H01M50/572—Means for preventing undesired use or discharge
    • H01M50/574—Devices or arrangements for the interruption of current
    • H01M50/579—Devices or arrangements for the interruption of current in response to shock
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
    • H01M50/00—Constructional details or processes of manufacture of the non-active parts of electrochemical cells other than fuel cells, e.g. hybrid cells
    • H01M50/50—Current conducting connections for cells or batteries
    • H01M50/572—Means for preventing undesired use or discharge
    • H01M50/574—Devices or arrangements for the interruption of current
    • H01M50/581—Devices or arrangements for the interruption of current in response to temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01M—PROCESSES OR MEANS, e.g. BATTERIES, FOR THE DIRECT CONVERSION OF CHEMICAL ENERGY INTO ELECTRICAL ENERGY
    • H01M2220/00—Batteries for particular applications
    • H01M2220/20—Batteries in motive systems, e.g. vehicle, ship, plane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Claims (11)

1. Multivariat cancerdiagnosefremgangsmåde, hvilken fremgangsmåde omfatter: a. opnå molekylærmarkørdata fra en enkelt prøve fra et individ omfattende en enkelt celle eller population af celler fra et væv, hvor molekylærmarkøren er en genetisk re-arrangering; b. opnå kvantitative cellemorfologimarkørdata fra den samme enkeltcelle eller population af celler som anvendt i trin (a), hvor cellemorfologimarkørdataet er nuklear størrelse, nuklear form og DNA-indhold; c. udføre en multivariabel analyse af enkeltprøven for at generere et multivariabelt analysedatasæt omfattende både kvantitative cellemorfologimarkørdata fra trin (b) og molekylærmarkørdata fra trin (a); d. sammenligne det multivariable analysedatasæt opnået i trin (c) med et referencemultivariabelt analysedatasæt dannet ved opnåelse af både molekylærmarkørdata og kvantitative cellemorfologimarkørdata fra cancer-og ikke-cancercelleprøver taget fra individer med kendt klinisk udfald, hvor molekylærmarkøren er en genetisk re-arrangering og cellemorfologimarkørdata er nuklear størrelse, nuklear form og DNA-indhold; og e. forudsige et klinisk udfald defineret ved specifikke kombinationer af cellemorfologimarkørdata og molekylærmarkørdata statistisk associeret med cancerudvikling, forekomst, metastaser eller andre determinanter af klinisk udfald set i reference-multivariable analysedatasæt.
2. Fremgangsmåden ifølge krav 1, hvor den genetiske re-arrangeringer en re-arrangering af ERG-genet.
3. Fremgangsmåden ifølge krav 1 eller 2, hvor enkeltcellen eller population af celler fra et væv er en enkeltcelle eller population af celler associeret med en cancer valgt fra gruppen bestående af leukæmi, lymfom, hjernecancer, rygmarvscancer, blærecancer, prostatacancer, brystcancer, livmoderhalscancer, livmodercancer, æggestokcancer, nyrecancer, spiserørscancer, lungecancer, koloncancer, bugspytkirtelcancer, og melanom.
4. Fremgangsmåden ifølge et hvilket som helst af kravene 2 til 3, hvor re-arrangeringen af ERG-genet detekteres ved in s/'tu-hybridisering.
5. Fremgangsmåden ifølge krav 4, hvor re-arrangeringen af ERG-genet detekteres ved fluorescens in s/tu-hybridisering (FISH) under anvendelse af fluorescensmærkede nukleinsyrer.
6. Fremgangsmåden ifølge et hvilket som helst af kravene 1 to 5, hvor nuklear størrelse, nuklear form og DNA-indhold detekteres under anvendelse af en fluorescerende DNA-farvningsteknik.
7. Fremgangsmåden ifølge krav 6, hvor den fluorescerende DNA-farvningsteknik er en DAPI-farvning.
8. Fremgangsmåden ifølge et hvilket som helst af kravene 5 til 7, hvor re-arrangeringen af ERG-genet og nuklear størrelse, nuklear form og DNA-indhold er kvantificeret ved fluorescens spektral billeddannelse for at tilvejebringe kvantitative spektral billeddannelsesdata.
9. Fremgangsmåden ifølge krav 8, hvor det multivariable analysedatasæt dannes under anvendelse af de kvantitative spektrale billeddannelsesdata.
10. Fremgangsmåden ifølge krav 9, hvor de kvantitative spektrale billeddannelsesdata er bølgelængdeopløsning, spatial opløsning og intensitetsopløsning af fluorescenssignalerne detekteret ved den fluorescerende DNA-farvningsteknik og den fluorescerende in s/tu-hybridisering.
11. Fremgangsmåden ifølge et hvilket som helst af kravene 2 til 10, hvor re-arrangeringen af ERG-genet er en insertion i ERG-genet, eller deletion af 5'-regionen af ERG, og cellemorfologimarkørdata er en uregelmæssig rundhed af cellekernerne.
DK12725639.4T 2011-05-09 2012-05-07 Spektral billeddannelse til måling af nukleære patologiske træk i cancerceller fremstillet til in situ analyse DK2707505T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161483928P 2011-05-09 2011-05-09
PCT/EP2012/058356 WO2012152747A2 (en) 2011-05-09 2012-05-07 Spectral imaging for measurement of nuclear pathology features in cancer cells prepared for in situ analysis

Publications (1)

Publication Number Publication Date
DK2707505T3 true DK2707505T3 (da) 2016-07-25

Family

ID=46208438

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12725639.4T DK2707505T3 (da) 2011-05-09 2012-05-07 Spektral billeddannelse til måling af nukleære patologiske træk i cancerceller fremstillet til in situ analyse

Country Status (8)

Country Link
US (3) US9951388B2 (da)
EP (1) EP2707505B1 (da)
JP (1) JP6208121B2 (da)
AU (1) AU2012252532B2 (da)
CA (1) CA2832328C (da)
DK (1) DK2707505T3 (da)
ES (1) ES2589507T3 (da)
WO (1) WO2012152747A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103149369B (zh) * 2013-03-20 2015-08-19 江苏元化生命科技有限公司 一种检测食管鳞癌标志物的蛋白质芯片及其试剂盒
DE102015203844A1 (de) 2015-03-04 2016-09-08 Carl Zeiss Meditec Ag Optiksystem und Operationsmikroskop
CN108449995B (zh) 2015-11-06 2022-02-01 文塔纳医疗系统公司 代表性诊断
CN111656179B (zh) 2017-11-13 2023-11-03 豪夫迈·罗氏有限公司 用于使用表位电泳进行样品分析的装置
US20210382002A1 (en) 2018-10-12 2021-12-09 Roche Sequencing Solutions, Inc. Detection methods for epitachophoresis workflow automation
EP3969583A1 (en) 2019-05-14 2022-03-23 F. Hoffmann-La Roche AG Devices and methods for sample analysis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989811A (en) * 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US6025128A (en) 1994-09-29 2000-02-15 The University Of Tulsa Prediction of prostate cancer progression by analysis of selected predictive parameters
US7218764B2 (en) 2000-12-04 2007-05-15 Cytokinetics, Inc. Ploidy classification method
US20040197839A1 (en) 2003-04-04 2004-10-07 Bioview Ltd. Methods of detecting cancer cells in biological samples
US8249326B2 (en) * 2005-11-25 2012-08-21 British Columbia Cancer Agency Branch Apparatus and methods for automated assessment of tissue pathology
CA2926831A1 (en) 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
WO2009047756A2 (en) * 2007-10-11 2009-04-16 Bioview Ltd. Methods and kits for diagnosing lung cancer
US20100226926A1 (en) 2009-03-09 2010-09-09 Bioimagene, Inc Method of Detection of Fluorescence-Labeled Probes Attached to Diseased Solid Tissue

Also Published As

Publication number Publication date
EP2707505A2 (en) 2014-03-19
JP6208121B2 (ja) 2017-10-04
US20180291464A1 (en) 2018-10-11
AU2012252532A1 (en) 2013-10-17
AU2012252532B2 (en) 2016-03-03
CA2832328C (en) 2019-06-18
US20140296088A1 (en) 2014-10-02
WO2012152747A3 (en) 2013-01-24
CA2832328A1 (en) 2012-11-15
US20150197811A9 (en) 2015-07-16
WO2012152747A2 (en) 2012-11-15
EP2707505B1 (en) 2016-06-08
US20220389523A1 (en) 2022-12-08
ES2589507T3 (es) 2016-11-14
US11441189B2 (en) 2022-09-13
US9951388B2 (en) 2018-04-24
JP2014530594A (ja) 2014-11-20

Similar Documents

Publication Publication Date Title
US20220389523A1 (en) Image acquisition methods for simultaneously detecting genetic rearrangement and nuclear morphology
JP6604960B2 (ja) バイオマーカー陽性の腫瘍細胞を識別するための医用画像解析
JP5040597B2 (ja) 評価システム、評価方法および評価プログラム
JP5184087B2 (ja) ガンの予後のためのマーカー候補を分析および最適化するための方法およびコンピュータープログラム製品
EP3553527A1 (en) Systems and compositions for diagnosing barrett's esophagus and methods of using the same
KR102412396B1 (ko) 객담유래 세포의 dna 메틸화 표현형결정에 의한 조기 폐암 검출
US20040197839A1 (en) Methods of detecting cancer cells in biological samples
JP2014530594A5 (da)
US8731845B2 (en) Method and a system for determining a target in a biological sample by image analysis
CN107847145B (zh) 光子结构和化学计量学病理系统
US10962544B2 (en) Methods of predicting progression of Barrett's esophagus
US20020012938A1 (en) Detection of epithelial dysplasia
US10598664B2 (en) Epithelial quantitation of histologically normal prostate tissue predicts the presence of cancer in tissue biopsies
CA2775315C (en) Methods for characterizing and isolating circulating tumor cell subpopulations
JP6592854B2 (ja) ｃ−ＭＹＣ遺伝子転座の判定方法
Berman et al. Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index
CN113557307A (zh) 端粒相关变量的测定方法及其在端粒相关疾病的诊断和/或预后中的用途
Padovani Jr et al. Morphometric analysis of nucleus and nucleolar organizer regions (NORs) in tongue squamous cell carcinoma (SCC)
Roepman et al. Microarray-based determination of ER, PR and HER2 receptor status: validation and comparison with IHC assessments
MONTIRONI PETER W. HAMILTON, PHD KATE E. WILLIAMSON, PHD
Padovani Jr et al. Análisis Morfométrico de Núcleos y Regiones del Organizador Nucleolar (NORs) en Carcinomas de Células Escamosas de la Lengua (SCC)
WO2002018658A9 (en) Detection of epithelial dysplasia